Oscar Tahuahua, Medical Oncology Fellow at the National Cancer Institute of Mexico, shared a post on X:
“Multicenter real-world cohort, n=410 patients
HER2DX integrates biology beyond standard pathology. In neoadj treated HER2+ disease, the HER2DX pCR score was the only independent predictor of pCR, remaining significant after adjustment for HR status, Ki67 & TILs.
The relapse-risk score identified aggressive, immune-cold phenotypes. In the T-DXd era, this informs escalation versus de-escalation decisions.”
Title: Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
Authors: Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera, Sandra Cobo, Blanca González-Farré, Eva Hernandez-Illan, Pedro Jares, Joan Antón Puig-Butillé, Montserrat Muñoz, Raquel Gómez-Bravo, Marta Tapia, Cristina Tebar, Cristina Saura, Santiago Escrivà-de-Romaní, Jesús Soberino, Javier Cortés, Serafin Morales, Kepa Amillano, Laia Paré, Patricia Villagrasa, Wesley Buckingham, Francisco Pardo, Joel Parker, Fara Brasó-Maristany, Eva Ciruelos, Rodrigo Sánchez-Bayona, Olga Martinez-Sáez, Juan Miguel Cejalvo, Aleix Prat
Read the Full Article.
More posts featuring Oscar Tahuahua.